The DOI matches its Crossref record; the references it cites are not checked yet.
Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The SGLT2 inhibitor dapagliflozin combined with cetuximab dramatically reduced carcinoembryonic antigen (CEA) and caused substantial shrinkage of metastatic tumour lesions.
“The SGLT2 inhibitor dapagliflozin combined with cetuximab dramatically reduced carcinoembryonic antigen (CEA) and substantial shrinkage of metastatic tumour lesions [37].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [37]
Citations
The citation lists haven’t been fetched yet
References 5 · Cited by 35
Metadata
- Authors
- Okada, J., Matsumoto, S., Kaira, K., Saito, T., Yamada, E., Yokoo, H., Katoh, R., Kusano, M., Okada, S., & Yamada, M.
- Affiliations
- Gunma University (JP)
- Gunma University Hospital (JP)
- Corresponding author
- Okada, Shuichi
- ORCID
- Venue
- Clinical Colorectal Cancer
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 17
- Issue
- 1
- Pages
- e45-e48
- ISSN
- 1533-0028 (ISSN-L)
- OpenAlex
- W2759264952
- Cited by
- 35
- References
- 5
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 11 · 2023: 2 · 2022: 3 · 2021: 5 · 2020: 1 · 2019: 3 · 2018: 1
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Colorectal Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- sodium-glucose cotransporter 2 inhibition, SGLT2 inhibitors, cetuximab, colon cancer, liver metastasis, carcinoembryonic antigen, tumor shrinkage, glucose transporter 1, GLUT1
- MeSH terms
- Cetuximab, Antineoplastic Agents, Immunological, Sodium-Glucose Transporter 2 Inhibitors, Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Benzhydryl Compounds, Carcinoembryonic Antigen, Colonic Neoplasms, Diabetes Mellitus, Type 2, Glucosides, Humans, Liver Neoplasms, Male, Neoplasm Recurrence, Local
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
